New Evidence Confirms Hormone Therapy Safe for Early Treatment of Menopause

BOCA RATON, Fla.--(BUSINESS WIRE)--Yesterday, the preliminary findings of the Kronos Early Estrogen Prevention Study (KEEPS) were highlighted confirming the safety and efficacy of hormone therapy for the treatment of menopause. The four-year study, although small, is the first in what is expected to be a long line of studies that will not only answer the question, “is hormone therapy safe,” but will also shed light on the safety and efficacy of bioidentical hormone therapies.

“The results of this study have been highly anticipated and, so far, the preliminary findings are fascinating”

BodyLogicMD, the nation’s largest network of highly-trained physicians specializing in bioidentical hormone therapy, has been following the study since the announcement of its design and purpose in 2004. “The results of this study have been highly anticipated and, so far, the preliminary findings are fascinating,” says Dr. Jennifer Landa, Chief Medical Officer of BodyLogicMD, responsible for the education and training of the growing network of physicians, currently boasting more than 50 expert bioidentical hormone doctors. “This long-term study is crucial in refuting the fears initiated by the Women’s Health Initiative and proving that bioidentical hormone therapy is safe and effective for menopause relief and disease prevention.”

This results released yesterday covered the arm of the study comparing the safety and efficacy of oral (synthetic) estrogen or transdermal (bioidentical) estrogen, when combined with micronized (bioidentical) progesterone, in the treatment of menopausal symptoms and risk of disease. The subjects were all females, aged 42 to 58 and within three years of menopause after randomization. The results have yielded positive outcomes for both treatments in comparison to a placebo. Namely, the improvements in the symptoms of menopause, but markers of disease were either unaffected or improved, except in the case of the oral estrogens, which yielded increase triglyceride levels.

There are other branches of the study that are seeking to offer more conclusive evidence on the effectiveness of these forms of hormone therapy in reducing the risk of disease and the impact on older female subjects. The release followed the announcement of these results at the North American Menopause Society (NAMS) meeting in Orlando, Florida. These preliminary results are expected to be published later this year.

About BodyLogicMD

Founded in 2003, BodyLogicMD physician-owned practices make up the nation’s largest and fastest growing network of the most highly-trained physicians specializing in bioidentical hormone replacement therapy. Integrated with fitness and nutrition, BodyLogicMD’s medically supervised programs are for men and women suffering from hormone imbalance associated with aging, including menopause and andropause.

BodyLogicMD comprises a network of physicians, who are pioneers of the anti-aging industry. The Chief Medical Officer of BodyLogicMD, Dr. Jen Landa, published her top-selling book in women’s health, The Sex Drive Solution for Women: Dr. Jen’s Power Plan to Fire-up Your Libido in January 2012. BodyLogicMD has also been featured as an expert resource on Oprah.com and in Suzanne Somers’ books, Knockout: Interviews with Doctors Who Are Curing Cancer and How to Prevent It and Break Through: Eight Steps to Wellness. Her third book, Ageless: The Naked Truth about Bioidentical Hormones dedicates an entire chapter to BodyLogicMD. The Florida Trend cover story in December 2009, featured BodyLogicMD as the national leader in the growing anti-aging industry. The BusinessWeek cover story in March 2006, features the BodyLogicMD start-up story.